T-E. Ciuleanu

机构：Institute of Oncology Prof. Dr. Ion Chiricuta

发表论文 73 篇 · 总被引 543 次 · h-index 13

代表论文

• Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial (2023 · ESMO Open · 被引 50)
• 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status (2021 · Annals of Oncology · 被引 25)
• 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC (2024 · Immuno-Oncology Technology · 被引 22)
• VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC (2023 · Annals of Oncology · 被引 13)
• 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) (2022 · Annals of Oncology · 被引 12)
• OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (2023 · Journal of Thoracic Oncology · 被引 11)